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Collagens represent the most abundant type of 
proteins in vertebrates and play crucial roles in 
the development, morphogenesis, and growth 
of many tissues (1). Besides their mechanical 
properties, collagens serve as substrates for cell 
attachment, migration, coagulation, and medi-
ate signaling events by binding to several cell 
surface receptors, such as integrins, discoidin 
domain receptors, glycoprotein VI (GpVI), and 
proteoglycan receptors (2).
Leukocyte-associated Ig-like receptor-1 
(LAIR-1) is a member of the Ig superfamily 
(IgSF), which is expressed on the majority of 
PBMCs and thymocytes (3). Antibody-induced 
cross-linking of the receptor in vitro delivers a 
potent inhibitory signal that is capable of inhibit-
ing cellular functions of NK cells, eff  ector T cells, 
B cells, and dendritic cell precursors (3–6). This 
inhibitory signal is dependent on phosphorylation 
of tyrosine residues located in immunoreceptor 
tyrosine-based inhibitory motifs (ITIMs) present 
in the cytoplasmic tail of LAIR-1 (7).
ITIM-bearing receptors are important for 
an appropriate immune response that needs to 
be tightly controlled by the opposing action of 
activating and inhibitory signals. Immune cells 
are potentially exposed to multiple activating 
signals in the tissues, and inhibitory receptors 
are required to set a threshold for cell activation 
and thus prevent unwanted immune reactions 
(8). Although all immune cells express multiple 
inhibitory receptors, these receptors have cru-
cial nonredundant functions, as underlined by 
receptor knockout mice that demonstrate en-
hanced sensitivity to autoimmune-like diseases 
caused by an over-activated immune system 
(9). The expression pattern of the receptors and 
the identity of their ligand determine at what 
stage of an immune response they are eff  ective. 
Thus far, all documented ligands for immune 
ITIM-bearing receptors are membrane mole-
cules, implying a regulatory role in cell–cell in-
teraction. Our fi  nding that collagens are ligands 
for an ITIM-bearing receptor reveals a novel 
mechanism of peripheral immune regulation 
by extracellular matrix proteins.
RESULTS AND DISCUSSION
Collagen XVII is a ligand for LAIR-1
By expression cloning, immunoprecipitation, 
and subsequent protein sequencing, we identi-
fi  ed transmembrane collagen XVII as a ligand 
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for LAIR-1 (Fig. S1 and supplemental Materials and meth-
ods, available at http://www.jem.org/cgi/content/full/jem.
20052554/DC1). The interaction was confi  rmed by specifi  c 
binding of human (h) LAIR-1-IgG to Ba/F3 cells stably 
transfected with hcollagen XVII (Fig. 1 A). Furthermore, rat 
(r) and mouse (m) LAIR-1–IgG bound to hcollagen XVII–
transfected cells but not to the untransfected parental cell 
line. Binding of hLAIR-1–IgG and mLAIR-1–IgG to hcol-
lagen XVII was blocked by anti–hLAIR-1 antibodies (8A8) 
or polyclonal anti–mLAIR-1 antibodies, respectively, dem-
onstrating the specifi  city of these interactions (Fig. 1, B and 
C). The association was divalent cation independent; EDTA 
did not aff  ect LAIR-1 fusion protein binding (not depicted). 
In addition, human LAIR-2, a putatively secreted protein 
that is 84% homologous to hLAIR-1 (10), interacted with 
hcollagen XVII (Fig. 1 A). Thus, collagen XVII is a ligand for 
LAIR-1 and LAIR-2, and, as we observed previously, ligand 
recognition occurs cross-species (11, 12).
To confi  rm that LAIR-1 expressed on cells can bind to 
collagen XVII, we measured formation of conjugates be-
tween LAIR-1 and collagen XVII–transfected K562 cells by 
fl  ow cytometry. We observed profound aggregation between 
mLAIR-1 and hcollagen XVII–expressing cells, an interac-
tion that was formed within minutes and remained stable for 
at least 24 h (Fig. 2, A and B). mLAIR-1–transfected cells 
were more effi   cient in forming conjugates with hcollagen 
XVII–transfected cells than hLAIR-1–transfected cells (Fig. 2 A). 
This diff  erence was evident both in the percentage of cells 
present in a conjugate (Fig. 2 A) and in the time after which 
optimal conjugate formation was observed (not depicted). 
This may indicate an intrinsic diff  erence between mouse and 
hLAIR-1 in affi   nity to the collagen XVII trimer.
LAIR-1 is a general collagen receptor
We investigated whether the previously observed binding 
of LAIR-1 to human tumor cell lines (11) correlated with 
collagen XVII expression. LAIR-1 ligand+ (11) HT29 colon 
carcinoma cells expressed collagen XVII, and pretreatment of 
these cells with Clostridium histolyticum collagenase abrogated 
both LAIR-1–IgG and anti–collagen XVII mAb binding 
(Fig. 3 A). The collagen XVII− breast carcinoma cell line 
SK-BR-3, however, also expressed a ligand for LAIR-1 that 
was removed after collagenase treatment, suggesting that 
LAIR-1 may bind to another collagen family member on 
these cells (Fig. 3 A). Indeed, transient expression of trans-
membrane collagens XIII and XXIII in 293T cells resulted in 
the binding of LAIR-1–IgG (Fig. 3 B). In addition, immobi-
lized nontransmembrane collagens I, II, and III were ligands 
for LAIR-1 (Fig. 3 C). LAIR-1–transfected K562 cells 
fi   rmly adhered to collagens, which coincided with cell 
spreading (Fig. 3 D). Both mouse and human LAIR-1–IgG 
immunoprecipitated hcollagen III from solution (Fig. 3 E). 
Figure 1.  Collagen XVII is a ligand for LAIR-1. (A) Ba/F3 cells trans-
fected with hcollagen XVII (fi  lled histograms) or the parental cell line (open 
histograms) were stained with the indicated LAIR fusion proteins (LAIR-
IgGs), hIgG isotype control (isotype), or anti–collagen XVII antibodies (anti-
hColXVII). (B) Anti–hLAIR-1 mAb (8A8) completely abrogated the hcollagen 
XVII/hLAIR-1–IgG interaction. (C) Polyclonal anti–mLAIR-1 antibodies ab-
rogated hcollagen XVII/mLAIR-1–IgG interaction, whereas control serum 
did not. Data shown are representative of three independent experiments.
Figure 2.  Collagen XVII– and LAIR-1–transfected cells form 
  aggregates. K562 cells transfected with hLAIR-1, mLAIR-1, or hcollagen 
XVII were either red or green fl  uorescently labeled, coincubated in various 
indicated combinations at 37°C, and analyzed by fl  ow cytometry (percent-
age of double-positive cell conjugates is indicated) (A) or by visual inspec-
tion for cell clustering (B). Data shown are representative of three 
independent experiments.JEM VOL. 203, June 12, 2006  1421
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Furthermore, insoluble collagen I fi  brils specifi  cally precipi-
tated LAIR-1 from hLAIR-1–transfected K562 cell lysates as 
well as from human PBMC lysates expressing endogenous 
LAIR-1 (Fig. 3 F). Additionally, mouse and human LAIR-
1–IgG bound specifi  cally to human skin tissue sections (Fig. 
3 G). The collagen I– and III–rich dermis stained brightly 
with LAIR-1–IgG, which was completely blocked by pre-
incubation of the fusion proteins with hcollagen I. We con-
clude that LAIR-1 is a receptor for multiple transmembrane 
and extracellular matrix collagens.
LAIR-1 is a high affi  nity collagen receptor
We measured affi   nity of the collagen–LAIR interaction by 
surface plasmon resonance (BIAcore). hLAIR-1–IgG bound 
Figure 3.  LAIR-1 is a collagen receptor. (A) SK-BR3 cells express a 
collagen ligand for LAIR-1 that is not collagen XVII. HT29 or SK-BR3 cells 
were stained with hLAIR-1–IgG or anti–collagen XVII mAb (fi  lled histo-
grams) with or without pretreatment with collagenase. Open histograms 
represent staining with isotype-matched control Ig. (B) 293T cells were 
transiently transfected with control vector (open histograms) or indicated 
HIS-tagged collagens (gray histograms) and stained with hLAIR-1–IgG 
(top) or anti-HIS antibody (bottom). Similar results were obtained using 
hLAIR-2–IgG, mLAIR-1–IgG, and rLAIR-1–IgG. (C) Fluorescently labeled wt 
K562 cells (open bars) or K562 cells expressing hLAIR-1 (black bars) or 
KIR3DL1 (gray bars) were monitored for their capacity to bind immobi-
lized collagens I, II, and III. Where indicated, cells were preincubated with 
anti–hLAIR-1 F(ab′)2 (8A8) fragments (hatched bars). Two other members 
of the IgSF (CD48 and CD80 transfected in K562 cells) did not associate 
with collagens (not depicted). Percentage of adhering cells relative to 
input is shown. One of three independent experiments is shown. 
(D) mLAIR-1–transfected K562 cells spread upon interaction with immo-
bilized collagen I. Spreading was also observed upon interaction with 
immobilized (GPO)10, but not (GPP)10 (not depicted). Nontransfected cells 
did not adhere to collagen I or (GPO)10 (not depicted). (E) Immunoprecipi-
tation using mLAIR-1–IgG, hLAIR-1–IgG, or control protein with (+) or 
without (−) purifi  ed hcollagen III. Interacting proteins were Western blot-
ted using anti–hcollagen III–specifi  c mAbs. Positive control represents 
purifi  ed collagen III. (F) Cell lysates from human PBMCs or hLAIR-1–
  transfected K562 were preincubated with or without anti–hLAIR-1 F(ab′)2 
fragments before incubation with insoluble collagen I fi  brils. Collagen 
fi  brils and interacting proteins were centrifuged, washed, and Western 
blotted using anti–hLAIR-1 mAbs. (G) Tissue sections of human skin 
stained with biotinylated mLAIR-1–IgG (middle) or control Ig (left) fol-
lowed by streptavidin horseradish peroxidase and counterstaining with 
hematoxylin. Staining was blocked by preincubation of mLAIR-1–IgG with 
purifi  ed collagen I (right). Staining with hLAIR-Ig gave similar results.1422  COLLAGENS ARE FUNCTIONAL LIGANDS FOR LAIR-1 | Lebbink et al. 
with high affi   nity to collagens I and III (Fig. 4 A), and its rela-
tively slow dissociation was characterized by a rapid initial 
phase and a slower secondary phase (Fig. 4 B). LAIR-1 bound 
to collagen with  40 times higher affi   nity than the well-
studied collagen receptor GpVI (13). Furthermore, the inter-
action was of 20–1,000-fold higher affi   nity as compared with 
most IgSF members interacting with their ligands (14). Al-
though purifi  ed LAIR-1–IgG bound directly to collagens I 
and III (Fig. 4 A), we cannot exclude that additional proteins 
might modulate the binding in vivo. A single triple-helical 
collagen I or III molecule interacted with  10.4 and 9.7 
LAIR-1 proteins, respectively (Fig. 4 A), and this high affi   n-
ity interaction was suffi   cient to arrest K562 cells expressing 
hLAIR-1 on collagen III–coated coverslips under fl  ow con-
ditions (Fig. 4 C).
LAIR-1 binds Gly-Pro-Hyp collagen repeats
Because LAIR-1 interacted cross-species with multiple colla-
gen molecules, we hypothesized that LAIR-1 bound to a 
common collagen-restricted structure. The collagens are a large 
family of trimeric molecules composed of three polypeptide 
α chains, which contain the sequence repeat (Gly-X-Y)n, 
X being frequently proline (P) and, after posttranslational 
modifi  cation, Y being hydroxyproline (O). The GPO triplet 
is almost exclusively present in collagenous molecules and al-
lows the formation of a triple helix, which is the main char-
acteristic feature of collagens (15). Immobilized triple-helical 
peptides composed of 10 repeated GPO triplets ((GPO)10, 
also known as collagen-related peptide) (16) bound hLAIR-
1-IgG (Fig. 4 D), whereas a corresponding triple-helical 
(GPP)10 peptide did not. Thus, LAIR-1 binds a common 
collagen motif in a hydroxyproline-dependent manner. 
hLAIR-1–IgG bound less effi   ciently to (GPO)10 peptide as 
compared with collagen, suggesting that apart from the GPO 
sequence, additional structural components are required for 
optimal interaction. Interestingly, (GPO)10, but not (GPP)10, 
is also a selective ligand for GpVI (16), a major player in 
platelet–collagen adhesive interactions leading to thrombus 
formation. Like LAIR-1, GPVI is a member of the IgSF and 
is encoded in the leukocyte receptor cluster on human chro-
mosome 19q13.4 (11).
Collagens directly cross-link LAIR-1 and inhibit 
degranulation of RBL-2H3 cells
To analyze whether collagen induces functional cross-linking 
of LAIR-1, we generated 2B4 NFAT-GFP reporter cells 
(17) expressing a chimeric protein consisting of the extracel-
lular domain of hLAIR-1 and the transmembrane and intra-
cellular domain of CD3ζ. Receptor engagement of cells 
expressing the hLAIR-1-CD3ζ chimera, but not the parental 
cells, via plate-bound collagens I, III, or anti–hLAIR-1 mAbs 
resulted in expression of GFP (Fig. 5 A). Pretreatment of re-
porter cells with anti–hLAIR-1 F(ab′)2 fragments abrogated 
the NFAT activation (not depicted). Collagens I and III are 
thus capable of cross-linking hLAIR-1.
We next investigated whether cross-linking of LAIR-1 
by extracellular matrix collagens leads to inhibition of im-
mune cell function in vitro. As a model, we used LAIR-1–
transfected RBL-2H3 cells, which express endogenous IgE 
receptor FcεRI (7). Incubation of RBL-2H3 hLAIR-1 trans-
fectants with TNP-specifi   c IgE and subsequent triggering 
with plate-bound TNP-conjugated BSA resulted in degranu-
lation of the cells and release of β-glucuronidase (Fig. 5 B). 
Simultaneous cross-linking of hLAIR-1 using plate-bound 
anti–hLAIR-1 mAb or collagen I or III caused marked inhi-
bition of degranulation (Fig. 5 B). A LAIR-1 mutant that is 
unable to signal because the tyrosine residues in the ITIM 
were changed to phenylalanine  (LAIR-1-FF) (7), could 
not inhibit the degranulation upon collagen interaction (Fig. 
5 C). Furthermore, plate-bound triple-helical (GPO)10 alone, 
but not (GPP)10, was capable of specifi  cally inhibiting the de-
granulation of RBL cells (Fig. 5 D), suggesting that other GPO 
repeat–bearing collagens also can inhibit immune cell function 
by binding to LAIR-1. The eff  ect was specifi  cally due to the 
LAIR-1–collagen interaction because preincubation of the 
cells with blocking anti–hLAIR-1 F(ab′)2 fragments com-
pletely abolished the inhibition (Fig. 5, B and D). Thus, extra-
cellular matrix collagens are functional ligands for the inhibitory 
LAIR-1 that can directly down-regulate immune responses.
Figure 4.  LAIR-1 is a high affi  nity collagen receptor. (A) Indicated 
concentrations hLAIR-1–IgG were injected at 20 μl/min sequentially through 
a BIAcore fl  ow cell containing  2,000-3,000 RU of directly immobilized 
collagen I (○), collagen III (□), or nothing. Each symbol represents the 
resonance unit at equilibrium and the corresponding concentration of the 
fusion protein. These data were used to determine the indicated Kd values. 
Control fusion proteins did not associate with collagen. (B) Rate of dis-
sociation of hLAIR-1–IgG from collagens I and III (not depicted) as moni-
tored by surface plasmon resonance. (C) K562 cells transfected with 
hLAIR-1 bind collagen III under fl  ow conditions. The indicated transfec-
tants were perfused at wall shear rates of 0.76 dynes/cm2 over collagen III–
coated coverslips. The number of binding cells was counted after 5 min 
(mean ± SEM, n = 6). (D) hLAIR-1 binds immobilized (GPO)10, but not 
(GPP)10. 780 nM hLAIR-1–IgG was injected at 5 μl/min through a BIAcore 
fl  ow cell containing  250 RU of immobilized (GPO)10 or (GPP)10.JEM VOL. 203, June 12, 2006  1423
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When immune cells migrate into the tissues, they are po-
tentially exposed to multiple activating signals. To ensure that 
they respond appropriately to these stimuli, inhibitory recep-
tors are required to set a threshold for cell activation (8). Our 
results show that collagen–LAIR-1 interactions can inhibit 
cell activation and, as such, may contribute to a dampening of 
the response. Under physiological conditions, immune cells 
present in the blood are not exposed to collagens (18). Their 
extravasation, however, results in interaction with collagen-
rich subendothelial structures, which may increase the thresh-
old for activation needed to keep these potentially dangerous 
cells in check. When immune cells reach an infl  ammatory 
  locus, the presence of specifi  c and strong activating stimuli 
given by antigen-presenting cells, cytokines, or pathogens 
will override the threshold and allow cells to become acti-
vated and mediate their function. Indeed, we observed that 
suboptimal activation via the FcεR was effi   ciently  down-
  regulated via the LAIR-1–collagen interaction, whereas max-
imal activation was not (not depicted). Regulation of the 
LAIR-1–collagen interaction can also occur by modulating 
LAIR-1 expression at diff  erent stages of diff  erentiation or ac-
tivation of immune cells, as was previously demonstrated for 
B cells (4), T cells (6), neutrophils (19), and dendritic cells 
(unpublished data). In addition, secreted LAIR-2 might serve 
as a regulator of LAIR-1 function by binding collagen, 
thereby circumventing the inhibitory potential of LAIR-1.
Loss of inhibitory immune receptors or down-regulation 
of ligands for these receptors can result in a hyperactivated 
immune system, leading to chronic infl  ammation and auto-
immunity (9). Collagens are implied in several human auto-
immune diseases. Collagen XVII, which we initially identifi  ed 
as a LAIR ligand, is an autoantigen in acquired blistering 
  disorders, e.g., bullous pemphigoid (20). Collagen II is an 
autoantigen in rheumatoid arthritis and systemic lupus 
  erythematosus (21), and collagen VII is an autoantigen in epi-
dermolysis bullosa acquisita (22). Potentially, autoantibodies 
targeting the various collagen molecules could interfere with 
the collagen–LAIR-1 interaction and thereby play a role in 
the pathology of these diseases.
Inhibitory receptors can be used by tumors and viruses to 
evade immune responses (23). Expression of several members of 
the collagen family, including collagens I, III, V, VI, XIII, XVII, 
XVIII, and XXIII, by neoplastic cells is associated with tumor 
progression (24–28). It is tempting to speculate that overexpres-
sion of collagens by tumor cells may enable these cells to sup-
press antitumor responses via the inhibitor, LAIR-1.
All previously documented ligands for ITIM-bearing re-
ceptors are membrane molecules, implying a regulatory role 
in cell–cell interaction. The functional interaction between 
extracellular matrix collagens and an inhibitory immune re-
ceptor presents a novel mechanism of immune regulation.
MATERIALS AND METHODS
Cells, transfectants, and cDNA. All cells were obtained from American 
Type Culture Collection. cDNA encoding hLAIR-1a and mLAIR-1a was 
cloned into the pMX-neo retroviral vector. Full-length mouse collagen 
XXIII was amplifi  ed by PCR from mouse lung cDNA and cloned in-frame 
with a COOH-terminal His6-tag and FLAG-tag in the pCEP4 vector. Full-
length hcollagen XVII, HIS-tagged hcollagen XIII, and hKIR3DL1 were 
provided by P.A. Khavari (Stanford University, Stanford, CA), T. Väisänen 
(University of Oulu, Oulu, Finland), and L.L. Lanier (University of California 
San Francisco, San Francisco, CA), respectively. The chimeric reporter con-
struct was generated by fusing the extracellular domain of hLAIR-1a to the 
transmembrane and intracellular domain of hCD3ζ.
Figure 5.  Collagens directly cross-link LAIR-1 and inhibit degran-
ulation of RBL-2H3 cells. (A) NFAT-GFP reporter cells (reference 17) 
transfected with hLAIR-1–CD3ζ chimera (bottom) or not (top) were incu-
bated with immobilized collagen I, collagen III, BSA, or anti–hLAIR-1 mAbs 
for 20 h, and GFP expression was analyzed by fl  ow cytometry. Percentage 
of GFP+ cells is indicated. (B) hLAIR-1–transfected RBL-2H3 (reference 7) 
cells were sensitized with IgE anti-TNP and incubated at 37°C in plates 
coated with TNP conjugated to BSA (0.8 μg/ml) in the absence or pres-
ence of plate-bound collagen I, collagen III, or anti–hLAIR-1 mAb (3.3 
μg/ml, fi  lled bars). Where indicated, cells were pretreated with 50 μg/ml 
anti–hLAIR-1 F(ab′)2 fragments (8A8, open bars). (C) The same experiment 
was performed using RBL-2H3 cells transfected with a LAIR-1 mutant in 
which both tyrosines in the intracellular tail are mutated to fenylalanines 
(hLAIR-1 FF). (D) hLAIR-1–transfected RBL-2H3 cells were sensitized with 
IgE anti-TNP and incubated at 37°C in plates coated with TNP conjugated 
to BSA (0.8 μg/ml) in the presence of plate-bound trimeric (GPO)10 or 
(GPP)10 peptides (coated at 3.3 μg/ml; fi  lled bars). Where indicated, cells 
were pretreated with 50 μg/ml anti–hLAIR-1 F(ab′)2 fragments (8A8, open 
bars). Degranulation was measured as described before. Typical degranu-
lation values ranged from 9 to 26% of the amount observed when all RBL 
cells were lysed by addition of 10% Triton. The relative percentage of de-
granulation was calculated as: 100*[(OD405 TNP + collagen − OD405 spon-
taneous release)/(OD405 TNP alone − OD405 spontaneous release)]. 
Spontaneous release was measured after coating with BSA alone. Mean 
values ± SEM of three independent experiments are shown. 1424  COLLAGENS ARE FUNCTIONAL LIGANDS FOR LAIR-1 | Lebbink et al. 
Retroviral-based constructs were packaged by the pCL-eco or pCL-
ampho system (29), and virus was used to infect Ba/F3, K562, or 2B4 
NFAT-GFP T cell hybridoma reporter cells (provided by L.L. Lanier). 3 d 
after transduction, transfectants expressing either hLAIR-1, mLAIR-1, hcol-
lagen XVII, hKIR3DL1, or hLAIR-1-CD3ζ were sorted for high ex  pression 
on the cell surface by using a fl  ow cytometer (FACSAria; BD Biosciences). 
hCollagen XVII expression was assessed by using the 233 mAb (provided by 
K. Owaribe, Nagoya University, Nagoya, Japan). mLAIR-1 was detected by 
using a biotinylated anti–mLAIR-1 mAb.
Detection of LAIR ligand. Chimeric proteins of the extracellular domain 
of rat, mouse, and hLAIR-1 or hLAIR-2 fused to the Fc region of human 
IgG1 were prepared, and cell lines were stained with these reagents in the 
absence or presence of blocking antibodies as described previously (11). 
When indicated, cells were incubated for 1 h with 100 U/ml of chromatog-
raphy-purifi  ed C. histolyticum collagenase type VII (Sigma-Aldrich) before 
staining with the fusion proteins.
Conjugate analysis. K562 transfectants were labeled for 5 min at room 
temperature with either PKH67 (green) or PKH26 (red; Sigma-Aldrich) ac-
cording to the manufacturer’s protocol. Cells were mixed at a ratio of 1:1 
and incubated at 37°C for 1.5 h for mLAIR-1–expressing cells and 5 h for 
hLAIR-1–expressing cells. Cells were gently resuspended before fl  ow cyto-
metric analysis or analysis by light microscopy.
Analysis of the binding of K562 transfectants to plate-bound collagens. 
96-well MAXIsorp (Nunc) fl  at-bottom plates were coated overnight at 4°C 
with purifi  ed collagens I, III (Sigma-Aldrich), II (Chemicon International), or 
BSA (100 μl/well, 20 μg/ml in PBS, 2 mM acetic acid). After washings, wells 
were blocked with 1% (wt/vol) BSA. Meanwhile, 5 × 106 cells/ml of wild-
type K562 cells or K562 transfectants were fl  uorescently labeled for 30 min at 
37°C with 5 μM calceine AM (Invitrogen) in PBS. Cells were washed twice 
with RPMI 1640 containing 1% FCS, 1.5 × 106 cells/ml in 100 μl medium 
were added to each well, and plates were incubated at 37°C for 2 h. Where in-
dicated, cells were preincubated with 50 μg/ml anti–hLAIR-1 F(ab′)2 (8A8) 
fragments for 15 min at room temperature before addition to the wells. Input 
fl  uorescence was determined by using a fl  uorescence plate reader (Fluoroskan 
Ascent; Thermo Labsystems). After incubation, the plates were fi  rmly fl  icked 
and washed four times in culture medium. The retained fl  uorescence was 
determined for each well as a percentage of input fl  uorescence.
Precipitation studies. For immunoprecipitation using LAIR-1-IgG, pro-
tein A/G PLUS agarose beads (Santa Cruz Biotechnology, Inc.) were coated 
with either mLAIR-1–IgG, hLAIR-1–IgG, or control protein. Immuno-
precipitation was performed for 2 h in the presence of 10 μg purifi  ed human 
collagen III (Sigma-Aldrich) and 1% BSA in Triton lysis buff  er (10 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, and 0.02% sodium azide) 
supplemented with 1 mM phenylmethylsulfonyl fl  uoride and protease inhib-
itors (Complete Mini EDTA-free protease inhibitor cocktail tablets; Roche). 
Immune complexes were washed with Triton wash buff  er (10 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 0.1% Triton X-100, and 0.02% sodium azide), 
supplemented with 1 mM phenylmethylsulfonyl fl   uoride, and boiled in 
Laemmli sample buff   er supplemented with 2-mercaptoethanol. Proteins 
were resolved by SDS-PAGE and transferred to Immobilon-P membranes 
(Millipore). Western blot analysis was performed with goat anti–human 
  collagen III antibodies (Southern Biotech) followed by horseradish 
  peroxidase–linked secondary antibodies. Proteins were detected by enhanced 
chemiluminescence (GE Healthcare).
For precipitations using insoluble collagen I fi  brils, collagen fi  brils were 
prepared by dialysis of a nonfi  brillar collagen I solution (1 mg/ml in 50 mM 
acetic acid) against 0.02 M sodium phosphate buff  er, pH 7.4, for 24 h at 4°C. 
Collagen fi  brils were separated from nonpolymerized collagen by centrifuga-
tion (5 min, 13,000 rpm, 4°C). Human PBMCs or K562 cells transfected 
with hLAIR-1 were preincubated with blocking anti–human LAIR-1 
F(ab′)2 fragments or left untreated, lysed in Triton lysis buff  er, and cleared 
by centrifugation (5 min, 13,000 rpm, 4°C). Cell lysates were incubated with 
insoluble collagen I fi  brils for 1 h at 4°C. Collagen fi  brils and interacting 
proteins were centrifuged, washed three times with Triton wash buff  er, and 
boiled in Laemmli sample buff  er supplemented with 2-mercaptoethanol. 
Proteins were resolved by SDS-PAGE and transferred to Immobilon-P 
membranes (Millipore). Western blot analysis was performed with mouse 
anti–hLAIR-1 mAbs (8A8) followed by horseradish peroxidase–linked sec-
ondary antibodies. Proteins were detected by enhanced chemiluminescence 
(GE Healthcare).
Human skin tissue section staining. Frozen tissue sections from healthy 
human skin were fi  xed in 10% acetone in the presence of 1.5% H2O2, and 
free biotin in the sections was blocked using the avidin/biotin blocking 
kit (Vector Laboratories). Tissue sections were stained with biotinylated 
mLAIR-1–IgG, hLAIR-1–IgG, or isotype-matched control Ig in the pres-
ence of 2% fetal calf serum and, when indicated, 100 μg/ml purifi  ed human 
collagen I (Sigma-Aldrich). After washing with PBS, sections were treated 
with streptABComplex/HRP (DakoCytomation) according to the manu-
facturer’s instructions, counterstained with hematoxylin, dehydrated, and 
mounted in DePeX mounting medium (British Drug House Ltd.). Sections 
were analyzed by light microscopy.
Reporter cell assay. 2B4 T cell hybridoma cells stably transduced with an 
NFAT-GFP reporter and hLAIR-1-CD3ζ were analyzed as described pre-
viously (17). In brief, 96-well MAXIsorp fl  at-bottom plates (Nunc) were 
coated overnight at 4°C with purifi  ed collagen I, collagen III, BSA, or anti–
hLAIR-1 antibodies (8A8) (100 μl/well, 10 μg/ml in PBS, 2 mM acetic 
acid). After washings, 3.5 × 105 cells/ml in 200 μl medium were added to 
each well, and plates were incubated at 37°C for 20 h and analyzed for GFP 
expression by fl  ow cytometry.
Surface plasmon resonance experiments. Surface plasmon resonance 
binding studies were performed by using a BIAcore2000 system (BIAcore). 
Approximately 2,000–3,000 response units (RU) of acid-soluble human col-
lagen type I or III (Sigma-Aldrich) were immobilized on a CM5 biosensor 
chip by using the amine coupling kit as instructed by the supplier. Immobi-
lized triple-helical peptides composed of GCO(GPO)10GCOG-NH2 
((GPO)10, also known as collagen-related peptide) and GCP(GPP)10GCPG-
NH2 ((GPP)10) were described previously (16). Approximately 250 RU 
(GPP)10 or (GPO)10 peptide trimers were immobilized by using a cysteine 
coupling kit according to the manufacturer’s instructions. Analysis was per-
formed in buff  er (125 mM NaCl, 2.5 mM CaCl2, 0.005% [vol/vol] Tween 
20, and 25 mM Hepes, pH 7.4) at 25°C at a fl  ow rate of 20 μl/min for col-
lagen I and III interaction studies and 5 μl/min for the immobilized pep-
tides. Binding of hLAIR-1–IgG to collagens I and III was specifi  c because 
nonspecifi  c binding to an uncoated control channel was <2% compared 
with collagen-coated channels. In addition, an irrelevant IgG fusion protein 
did not bind to the collagen-coated surface. hLAIR-1–IgG dimer concen-
tration was calculated based on a theoretical mass of 85.2 kD (corrected for 
removal of leader peptide). Increasing concentrations of hLAIR-1–IgG were 
injected and allowed to reach an equilibrium plateau for 10 min. The delay 
between injections was 13 min, during which time the biosensor chip was 
fl  ushed with buff  er. In the peptide-binding studies, biosensor chips were 
  regenerated by injection of 0.1 M H3PO4 (2 min, 5 μl/min).
Dissociation constants (Kd) and the number of binding sites expressed as 
the response at infi  nite hLAIR-1–IgG concentration (Bmax) were calculated 
as follows. First, the response at equilibrium (Req) was calculated for each 
association curve. Subsequently, Kd and Bmax were determined from the 
binding isotherms (Req plotted against hLAIR-1–IgG concentration) by the 
fi  tting equation Req = Bmax*[hLAIR-1–IgG]/(Kd + [hLAIR-1–IgG]). 
The fi  t was calculated by using GraphPad Prism (GraphPad Prism version 
3.0 for Windows; GraphPad Software). Bmax values were converted to 
number of hLAIR-1–IgG molecules interacting with a single collagen trimer 
by using the theoretical mass of hLAIR-1–IgG (85.2 kD) versus collagens I 
and III (416.7 and 415.7 kD, respectively).JEM VOL. 203, June 12, 2006  1425
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The dissociation of hLAIR-1–IgG in the presence of buff  er was fol-
lowed for at least 13 h, and Koff   values were calculated by using the Biaeval-
uation software version 3.0.1.
Perfusion studies. Perfusions were performed in a single-pass perfusion 
chamber as described previously (30). In brief, collagen type III was solu-
bilized in 50 mM acetic acid and sprayed onto glass coverslips by using a 
  retouching airbrush (Badger model 100; Badger Brush) at a density of 
6.5 μg/cm2. Afterward, coverslips were blocked for 1 h at room temperature 
with 1% human albumin in PBS. Wild-type or transfected K562 cells were 
then perfused for 5 min at a shear rate of 0.75 dyne/cm2 at 37°C. After per-
fusion, slides were washed with Hepes buff  er (10 mm Hepes, 150 mm NaCl, 
pH 7.35), fi  xed in 0.5% glutaraldehyde in PBS, dehydrated in methanol, and 
stained with May-Grünwald and Giemsa. Adhered K562 cells were counted 
by using light microscopy and presented as number of cells per mm2.
Online supplemental material. Fig. S1 shows the identifi  cation of mouse 
collagen XVII as a ligand for mLAIR-1. Supplemental Materials and methods 
describe the identifi  cation of collagen XVII as a ligand for LAIR-1. The online 
supplemental material is available at http://www.jem.org/cgi/content/full/
jem.20052554/DC1.
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